<DOC>
	<DOC>NCT01955044</DOC>
	<brief_summary>The purpose of this study is to determine if buccal administration of a concentrated formulation of long-chain polyunsaturated fatty acids (LCPUFA) can help to maintain docosahexaenoic acid (DHA) levels in extremely low birth weight (ELBW) infants.</brief_summary>
	<brief_title>PUFA Supplementation in Premature Infants</brief_title>
	<detailed_description>This will be a multi-center, randomized, placebo controlled, double blind trial. Two doses of PUFA will be compared to placebo- a "high" dose and a "low" dose. ELBW infants will be enrolled into this study.</detailed_description>
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Birth Weight</mesh_term>
	<criteria>a) Premature infant born at gestational age less than 34 weeks b) Birth weight less than 1000 grams c) Legally authorized representative is able to provide written informed consent within the first 72 hours of life, prior to the performance of an protocolspecified evaluations or procedures a) infants with known metabolic disorder b) infants with known congenital gastrointestinal anomaly c) infants who are deemed to be inappropriate for enrollment per attending neonatologist</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>72 Hours</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>neonatal prematurity</keyword>
	<keyword>infant, extremely low birth weight</keyword>
	<keyword>fatty acids, polyunsaturated</keyword>
</DOC>